Corrigendum to - Chitosan modified 5-fluorouracil nanostructured lipid carriers for treatment of diabetic retinopathy in rats: A new dimension to an anticancer drug, Vol. 224, 1 January 2023, Pages 810-830 (International Journal of Biological Macromolecules (2023) 224 (810–830), (S0141813022024102), (10.1016/j.ijbiomac.2022.10.168))

The authors regret to inform the editors and readers about inadvertent errors identified in the presentation of Figs. 10, 11, 12, and 13. The inaccuracies pertain to sub-image duplication issues and a typographical error in unit representation. Specifically, in Fig. 10, duplication of sub-images (Groups I, II, III, and IV after 6 h, as well as Group IV after 5 min) has been identified and rectified. New sub-images for this figure are now provided. Similarly, in Fig. 11, depicting the results of the anti-angiogenesis study by CAM assay, duplication in sub-images of Groups III and IV has been replaced with the new sub-images. In Fig. 12, representing fundus imaging for rats in Group IV (before treatment) and Groups I and II (20 days after treatment), duplication in sub-images has been identified and replaced with new sub-image. Additionally, in Fig. 13, a sub-image from the control group was inadvertently duplicated in Group III and has been replaced with the new sub-image. In the section 3.14.2.2. Histopathological examination, the unit “mm” should be read as “μm.” The corrected Figs. 10, 11, 12, and 13 are included below. These corrections do not impact the results, data interpretation, or conclusions presented in the study. Authors appreciate the understanding of the editorial board and readers.